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Abstract
Background: Previous research indicates a role of adipokines in inflammation and osteogenesis. Hence
adipokines might also have a pathophysiological role in inflammation and new bone formation in patients
with ankylosing spondylitis (AS). The aim of this study was to investigate the role of adipokine serum levels
as predictors of radiographic spinal progression in patients with AS.
Methods: A total of 120 patients with definite AS who completed a 2-year follow up in the ENRADAS trial
were included in the current study. Radiographic spinal progression was defined as: (1) worsening of the
modified Stoke Ankylosing Spondylitis spine (mSASSS) score by ≥2 points and/or (2) new syndesmophyte
formation or progression of existing syndesmophytes after 2 years. Serum levels of adipokines (adiponectin
(APN) and its high molecular weight form (HMW-APN), chemerin, leptin, lipocalin-2, omentin, resistin, visfatin)
were measured using enzyme-linked immunosorbent assays.
Results: There was a significant association between radiographic spinal progression and both leptin and
HMW-APN. Baseline serum levels of both adipokines were lower in patients who showed radiographic spinal
progression after 2 years. This association was especially evident in men; they had generally lower leptin and
HMW-APN serum levels as compared to women. The inverse association between adipokines and radiographic
spinal progression was confirmed in the logistic regression analysis: the odds ratios (OR) for the outcome
“no mSASSS progression ≥2 points” were 1.16 (95% CI 1.03 to 1.29) and 1.17 (95% CI 0.99 to 1.38), for leptin
and HMW-APN, respectively; for “no syndesmophyte formation/progression” the respective OR were 1.29
(95% CI 1.11 to 1.50) and 1.18 (95% CI 0.98 to 1.42), adjusted for the presence of syndesmophytes at baseline,
C-reactive protein at baseline, sex, body mass index (BMI), non-steroidal anti-inflammatory drugs intake score
over 2 years, and smoking status at baseline.
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Conclusion: Serum leptin and HMW-APN predict protection from spinal radiographic progression in patients
with AS. Women generally have higher leptin and HMW-APN serum levels that might explain why they have
less structural damage in the spine as compared to male patients with AS.
Trial registration: EudraCT: 2007-007637-39. ClinicalTrials.gov, NCT00715091. Registered on 14 July 2008.
Keywords: Axial spondyloarthritis, Ankylosing spondylitis, Leptin, Adiponectin, Adipokine, Radiographic
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Background
Ankylosing spondylitis (AS) is a chronic inflammatory
disease belonging to a family of spondyloarthritides
(SpA), which is characterized by inflammation in the
pelvis and the spine with subsequent new bone forma-
tion that might lead to partial or total ankylosis of the
spine. New bone formation in the spine, and particularly
development of specific bony bridges between the verte-
bral bodies, is usually assessed on spinal radiographs and
is referred to as radiographic spinal progression. It has
been shown in the past that radiographic spinal progres-
sion and disease activity are two main determinants of
spinal mobility and functional status in AS [1–3]. How-
ever, there is substantial individual variation in the radio-
graphic spinal progression rates in AS [4, 5]. It has been
shown that baseline syndesmophytes [4, 5], inflamma-
tory activity as assessed by C-reactive protein (CRP), by
the Ankylosing Spondylitis Disease Activity Score
(ASDAS), or by the presence of inflammatory changes
on magnetic resonance imaging (MRI) [6–12], and
cigarette smoking [13] are factors associated with more
rapid radiographic spinal progression. Further, several
biomarkers in the blood were found to be positively as-
sociated with new bone formation in the spine: the
already mentioned CRP [7], matrix-metalloproteinase-3
[14], vascular endothelial growth factor [15], calprotectin
[16], and the adipokine, visfatin [17]. Some biomarkers,
such as sclerostin [18] and dickkopf 1 [19], have been
associated with radiographic spinal progression, suggest-
ing that these molecules might have a protective effect.
Identification of biomarkers related to the develop-
ment of structural damage in AS helps not only to
predict progression (there are currently no proven thera-
peutic options to retard progression; however, this
might, change in the near future), but it also helps us to
better understand disease mechanisms. For instance,
until now, the reason why men with AS develop more
structural damage in the axial skeleton than women has
not been explained [5, 20].
Adipokines are biologically active substances, which
are synthesized and released by fat tissue. They have a
wide range of regulatory functions not only in energy
metabolism, but also in inflammation and osteogenesis
[21, 22]. The role of adipokines in the development of
inflammation and new bone formation in AS, however,
is as yet unclear. The aim of the present study was to in-
vestigate the association between adipokine serum levels
and radiographic spinal progression in patients with AS.
Methods
Patients
Altogether 120 patients from the trial, Effects of NSAIDs
on Radiographic Damage in AS (ENRADAS), who com-
pleted the study per protocol and for whom serum was
available, were included in the analysis. Serum samples
were not available for two patients who completed the
study per protocol, and these patients were excluded,
therefore, from the current study. Baseline characteris-
tics of the 120 patients included in this analysis are
shown in Table 1. The design of the ENRADAS trial has
been described in detail elsewhere [23]. Briefly, ENRA-
DAS was a prospective, randomized, controlled trial
aimed at investigation of the influence of non-steroidal








Age, years 42.9 ± 10.3 40.7 ± 9.7 45.1 ± 10.4
Male patients, n (%) 82 (68.3) 43 (70.5) 39 (66.1)
Symptom duration, years 14.8 ± 12.2 12.8 ± 11.4 16.9 ± 12.7
HLA-B27 positive, n (%) 108 (90) 54 (88.5) 54 (91.5)
ASDAS-CRP 2.8 ± 0.7 2.7 ± 0.7 2.8 ± 0.7
BASDAI, points NRS (0–10) 4.2 ± 1.5 4.1 ± 1.5 4.2 ± 1.5
BASFI, points NRS (0–10) 3.3 ± 2.2 2.9 ± 2.1 3.7 ± 2.2
CRP, mg/L 10.3 ± 12.1 7.9 ± 7.4 12.6 ± 15.2
CRP > 5 mg/L, n (%) 68 (57.1) 33 (55) 35 (59.3)
BASMI, points (0–10) 2.6 ± 2.2 2.2 ± 2.1 3.0 ± 2.3
mSASSS, points 13.8 ± 17.2 11.1 ± 15.6 16.6 ± 18.4
Patients with syndesmophytes
at baseline, n (%)
68 (56.7) 32 (52.5) 36 (61.0)
BMI, kg/m2 27.2 ± 5.3 27.3 ± 5.2 27.2 ± 5.4
Characteristics are presented as mean ± standard deviation unless indicated
otherwise. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath
Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing
Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology
Index, BMI body mass index, CRP C-reactive protein, mSASSS modified Stoke
Ankylosing Spondylitis Spine Score
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anti-inflammatory drugs (NSAIDs) on radiographic
spinal progression in patients with AS. Patients were
randomly assigned to treatment with diclofenac either
continuously or on demand for a period of 2 years.
Other NSAIDs in the same equivalent dose were allowed
in patients with diclofenac intolerability; however, about
2/3 of the patients remained on diclofenac until the end
of year 2. Tumor necrosis factor (TNF)α blockers were
not allowed in the trial. There was no difference in
radiographic spinal progression between patients who
took NSAIDs continuously and those who took them on
demand, justifying the decision to pool both treatment
groups.
Assessment of radiographic spinal progression
Radiographs of the lumbar and cervical spine (lateral
projection) were obtained at baseline and after a period
of 2 years. Radiographs were centrally collected, digi-
tized, anonymized, and subsequently scored by two
experienced and calibrated readers (KGH and DP) in a
randomly selected and concealed order according to the
modified Stoke Ankylosing Spondylitis Spine Score
(mSASSS) system [24]. The mean mSASSS was calcu-
lated from the two readers’ scores. Radiographic spinal
progression was defined as: (1) mSASSS worsening by
≥2 points after 2 years, and/or (2) development of at
least one new syndesmophyte or progression of two
single syndesmophytes into a bridging syndesmophyte,
in the opinion of both readers after 2 years.
Measurement of adipokine serum levels
Adipokine serum levels were measured at baseline and
after 2 years of follow up (week 100) using commercially
available enzyme linked immunosorbent assays (ELISA).
The following adipokines were selected based on data
from the available literature [25, 26] indicating a possible
association with bone metabolism and/or inflammation:
adiponectin (APN) (BioVendor - Research and Diagnos-
tic Products, Czech Republic) and its high molecular
weight form (HMW-APN) (R&D Systems, MN, USA),
chemerin (BioVendor - Research and Diagnostic Prod-
ucts), leptin (Invitrogen, CA, USA) lipocalin-2 (R&D
Systems), omentin (BioVendor - Research and Diagnos-
tic Products), resistin (Adipogen International,
Switzerland), and visfatin (Adipogen International).
Statistical analysis
First, we analyzed differences in the mean adipokine
serum levels between groups with and without radio-
graphic spinal progression (Mann-Whitney U test).
Adipokines with significantly different baseline serum
levels in progressors and non-progressors were further
analyzed. Since adipokines are mainly produced by adi-
pose tissue and their serum levels correlate with body
mass index (BMI) [25–27], the values were corrected for
BMI by calculating an adipokine/BMI ratio that was
used in the analysis in addition to the measured serum
levels. Further, an HMW-APN/APN ratio reflecting a
proportion of a more biologically active form of APN in
the total APN [28] was calculated and included in the
analysis. For the analysis of the influences of the treat-
ment arm on the change in serum levels of adipokines,
we performed the non-parametric Wilcoxon test on the
paired measures, and an analysis of covariance
(ANCOVA) with adjustment for the baseline adipokine
levels. Receiver operating characteristic (ROC) analysis
was performed to evaluate the adipokines as predictors
of radiographic spinal progression. The association be-
tween serum adipokines and radiographic spinal pro-
gression was further explored in the logistic regression
analysis. The parameter estimates were adjusted for the
presence of syndesmophytes at baseline, baseline CRP,
sex, BMI (for crude adipokine serum levels and the
HMW-APN/APN ratio), NSAID intake score over
2 years, and smoking status at baseline. A p value <0.05
was considered to be statistically significant.
Results
A total of 29 patients had radiographic progression de-
fined as mSASSS worsening by ≥2 points after 2 years;
25 patients had syndesmophyte formation/progression.
The intraclass correlation coefficient (ICC) between the
two readers of the X-rays was good: the ICC was 0.96
for baseline and 0.95 for year-2 X-rays; the ICC for
change in the mSASSS was 0.50 [23].
Adipokine serum levels in patients with and without
radiographic spinal progression are presented in Table 2.
There were significant differences between progressors
and non-progressors in the baseline serum levels of
leptin and HMW-APN (and to a further extent in the
HMW-APN/APN ratio). Therefore, these adipokines
were included in the subsequent analysis.
HMW-APN serum levels did not differ between the
two treatment arms (NSAIDs continuously vs. on de-
mand) at baseline and after 2 years of follow up; there
was, however, a difference in the leptin levels at baseline
(but not at year 2): 13.6 ± 13.2 ng/mL in the continuous
intake group vs. 15.5 ± 12.6 ng/mL in the on-demand
group, p = 0.046. Overall, there was an increase in the
leptin level after 2 years in both treatment groups
(continuous vs. on-demand NSAIDs); this was statisti-
cally significant in the continuous treatment group only:
increase of 13.6 ± 13.2 ng/ml to 15.6 ± 15.6 ng/mL, p =
0.002. However, in the ANCOVA, there was no statisti-
cally significant difference in the change in the leptin
serum level: increase of 2.0 ± 4.84 ng/mL in the continu-
ous vs. 1.26 ± 7.43 ng/mL in the on-demand group, p =
0.405, adjusted for baseline leptin. Further, there was no
Hartl et al. Arthritis Research & Therapy  (2017) 19:140 Page 3 of 11
significant association between change in leptin and
HMW-APN (or the BMI-corrected values) over 2 years
and radiographic spinal progression. Treatment had no
effect on the levels of other adipokines.
There was no evidence of association between radio-
graphic spinal progression and BMI in this patient
population: BMI at baseline was 26.9 ± 4.1 kg/m2 vs. 27.4 ±
5.6 kg/m2 in patients with and without mSASSS worsening
by ≥2 points, respectively, p = 0.93, and 28.1 ± 6.6 kg/m2 vs.
27.1 ± 4.9 kg/m2 in patients with and without syndesmo-
phytes formation respectively, p = 0.58.
There was no meaningful correlation between leptin
and HMW-APN serum levels, and no correlation with
serum CRP. In the ROC analysis, baseline serum leptin,
the leptin/BMI ratio, serum HMW-APN, the HMW-
APN/BMI ratio, and the HMW-APN/APN ratio were
good predictors of no mSASSS progression ≥2 points
and of no syndesmophyte formation/progression (Fig. 1).
Leptin and the leptin/BMI ratio was generally a slightly
better predictor as compared to HMW-APN.
Remarkably, male patients with AS had significantly
lower levels of leptin and HMW-APN (and BMI-
adjusted values and HMW-APN/APN ratio) compared
to women (Table 3). In the analysis stratified by sex, the
association between lower leptin and HMW-APN levels
and radiographic spinal progression was evident in men
only (Table 4). Furthermore, women had significantly
lower mSASSS at baseline and after 2 years of follow up
compared to men (7.9 ± 12.6 vs. 16.2 ± 18.2, respectively,
p = 0.015 at baseline and 8.6 ± 12.9 vs. 17.4 ± 19.0,
respectively, p = 0.011 after 2 years of follow up).
We further explored an association between leptin or
HMW-APN and radiographic spinal progression in the
logistic regression analysis (Table 5). Serum leptin and
the leptin/BMI ratio were significantly inversely associ-
ated with radiographic spinal progression; this remained
significant after adjusting for factors considered as con-
founders. The same trend was observed for HMW-APN
(crude and BMI-adjusted levels), but this was not statis-
tically significant. However, the HMW-APN/APN ratio
was inversely associated with radiographic spinal pro-
gression in the logistic regression analysis (Table 5).
Similar to the data presented in Table 4, the association
between serum adipokines levels and radiographic spinal
progression was evident in men but not in women when
analyzed separately (Table 6).
Discussion
In the current study we investigated the association
between serum adipokines and radiographic spinal pro-
gression in patients with AS. We report for the first time
that baseline leptin and HMW-APN serum levels, and
to a further extent the HMW-APN/APN ratio were in-
versely associated with (i.e., predicted protection against)
Table 2 Levels of adipokines in patients with AS with and without radiographic spinal progression after 2 years
Adipokine mSASSS progression
≥2 points (n = 29)
No mSASSS progression
≥2 points (n = 91)
Pa Syndesmophyte formation/






Leptin, ng/mL 10.5 ± 9.0 16.4 ± 13.7 0.003 10.2 ± 9.6 16.2 ± 13.4 0.003
APN, μg/mL 10.1 ± 4.8 10.7 ± 4.4 0.366 9.5 ± 3.7 10.8 ± 4.6 0.210
HMW-APN, μg/mL 4.95 ± 3.52 6.35 ± 4.15 0.045 4.53 ± 2.86 6.40 ± 4.22 0.026
Lipocalin-2, ng/mL 308.4 ± 424.8 197.1 ± 188.8 0.668 257.9 ± 361.3 215.1 ± 238.9 0.851
Chemerin, ng/mL 211.5 ± 54.2 222.6 ± 53.6 0.356 223.4 ± 57.8 219 ± 52.9 0.831
Omentin, ng/mL 455.1 ± 168.3 425.8 ± 131.7 0.477 477.8 ± 164.7 421 ± 132.8 0.122
Resistin, ng/mL 37.7 ± 27.9 30.4 ± 25.3 0.098 35.6 ± 25.4 31.3 ± 26.2 0.161
Visfatin, ng/mL 44.7 ± 80.3 42.2 ± 58.9 0.484 39.98 ± 83.4 43.4 ± 58.7 0.151
Year 2
Leptin, ng/mL 13.4 ± 12.8 17.5 ± 16.0 0.044 11.7 ± 9.8 17.7 ± 16.3 0.032
APN, μg/mL 9.1 ± 3.8 11.0 ± 5.9 0.129 8.6 ± 3.6 11.1 ± 5.8 0.029
HMW-APN, μg/mL 5.06 ± 3.31 5.99 ± 3.88 0.185 4.55 ± 2.8 6.08 ± 3.92 0.071
Lipocalin-2, ng/mL 235 ± 229.3 273 ± 311.1 0.762 194.7 ± 160.3 281.8 ± 316.7 0.613
Chemerin, ng/mL 216.2 ± 60.3 213 ± 56.7 0.990 218 ± 61.9 212.6 ± 56.4 0.893
Omentin, ng/mL 444.7 ± 133.6 426.4 ± 134.6 0.359 452 ± 139.9 425.3 ± 132.6 0.268
Resistin, ng/mL 47.4 ± 84.3 62.4 ± 204.8 0.332 49.8 ± 91 61.1 ± 200.4 0.500
Visfatin, ng/mL 43.6 ± 70 42.6 ± 62.3 0.627 43.9 ± 75.2 42.6 ± 61.2 0.499
AS ankylosing spondylitis, APN adiponectin, HMW-APN high molecular weight adiponectin, mSASSS modified Stoke Ankylosing Spondylitis Spine Score.
aMann-Whitney U test
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radiographic spinal progression. Initially, we investigated
eight adipokines and only those with evidence suggesting
an association with radiographic progression were en-
tered the main analysis. We have chosen the homoge-
neous population of the ENRADAS trial consisting of
patients with advanced AS. The lack of differences in
radiographic spinal progression between the study arms
justified pooling both groups of patients (treated with
NSAIDs continuously or on demand). However, due to
some change in the leptin level over 2 years that was
especially evident in the continuous treatment group,
the parameter estimates in the regression analysis were
adjusted for NSAID intake.
In the study population, leptin and HMW-APN levels
were higher in female patients with AS compared to
male patients, even after adjustment for BMI. At the
Fig. 1 Receiver operating characteristic analysis: association between leptin and high molecular weight adiponectin (HMW-APN) serum levels and
radiographic spinal progression after 2 years. Baseline serum levels of leptin and HMW-APN shown as crude values and as values corrected for
body mass index and adiponectin (only HMW-APN). mSASSS modified Stoke Ankylosing Spondylitis Spine Score, AUC area under the curve
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same time, there was no association between BMI and
radiographic spinal progression. There are data on
gender-dependent differences in adipokine levels in the
general population [29, 30]. In one study, leptin and
APN levels were higher in women than in men inde-
pendent of BMI or waist-to-hip ratio [29], while in an-
other study such an association was shown for leptin,
but not for adiponectin [30]. Similarly, differences in adi-
pokine levels between male and female patients have
also been described in patients with AS [17, 31]. Such an
association between sex and adipokine levels is especially
interesting in the context of the current study, since the
women in our study also had significantly lower
mSASSS scores than men. It has been shown several
times that female patients with AS develop new bone
formation to a lesser extent than male patients with AS [5,
20]. Therefore, we can speculate that leptin and HMW-
APN might be biomarkers (or even pathophysiological
factors) linking gender with radiographic spinal progres-
sion in patients with AS.
Remarkably, in the analyses stratified by sex, an associ-
ation between adipokines and radiographic spinal pro-
gression was evident in male patients only. On the one
hand, the absence of association between serum adipo-
kine and radiographic spinal progression in female pa-
tients could be related to the smaller sample size and a
small number of progressors in the female group. On
the other hand, female patients had generally higher
levels of leptin and adiponectin in comparison to male
patients, suggesting that in female patients who pro-
gressed after 2 years, there could have been other factors
playing a part.
In our previous study involving patients from the
German Spondyloarthropathy Inception Cohort (GES-
PIC) cohort, who had early axial SpA, we found a posi-
tive association between visfatin and radiographic spinal
progression; leptin and HMW-APN were not investi-
gated [17]. In the current study, we found only a trend
for such an association for visfatin that might be related
to the differences in disease duration in the GESPIC
(early disease) and ENRADAS (rather advanced disease)
studies or to the test system used.
Until now, serum adipokines and their relationship to
clinical or radiographic parameters in AS have only been
investigated in a few small trials. In some studies, leptin
serum was found to be lower in patients with AS com-
pared to healthy controls [32–34], but in others there
were either no differences or even higher leptin serum
Table 3 Sex-related differences in serum leptin and high
molecular weight adiponectin at baseline
Males (n = 82) Females (n = 38) Pa
Leptin, ng/mL 10.6 ± 6.9 24.4 ± 17.3 <0.001
Leptin/BMI 0.37 ± 0.19 0.84 ± 0.47 <0.001
HMW-APN, μg/mL 5.07 ± 3.06 8.04 ± 5.07 <0.001
HMW-APN/BMI 0.19 ± 0.13 0.32 ± 0.23 0.001
HMW-APN/APN 0.52 ± 0.23 0.61 ± 0.22 0.020
APN adiponectin, HMW-APN high molecular weight adiponectin, BMI body
mass index. aMann-Whitney U test
Table 4 Baseline serum leptin and HMW-APN in relation to radiographic spinal progression after 2 years
All patients (n = 120) Male patients (n = 82) Female patients (n = 38)














Leptin, ng/mL 10.5 ± 9.0 16.4 ± 13.7 0.003 7.0 ± 4.7 11.9 ± 7.1 0.001 21.7 ± 10.5 25.0 ± 18.6 0.96
Leptin/BMI 0.38 ± 0.31 0.57 ± 0.38 0.001 0.25 ± 0.14 0.42 ± 0.19 <0.001 0.78 ± 0.35 0.86 ± 0.49 0.84
HMW-APN, μg/mL 4.95 ± 3.52 6.35 ± 4.15 0.045 3.93 ± 2.56 5.49 ± 3.15 0.018 8.16 ± 4.37 8.02 ± 5.27 0.75
HMW-APN/BMI 0.19 ± 0.14 0.25 ± 0.19 0.089 0.15 ± 0.11 0.21 ± 0.13 0.052 0.32 ± 0.18 0.33 ± 0.24 0.84
HMW-APN/APN 0.47 ± 0.19 0.57 ± 0.23 0.024 0.42 ± 0.14 0.56 ± 0.24 0.033 0.62 ± 0.25 0.60 ± 0.22 0.82














Leptin, ng/mL 10.2 ± 9.6 16.2 ± 13.4 0.003 9.0 ± 9.1 11.1 ± 5.9 0.018 16.4 ± 10.9 25.3 ± 17.8 0.27
Leptin/BMI 0.33 ± 0.22 0.57 ± 0.39 0.001 0.29 ± 0.19 0.40 ± 0.18 0.006 0.56 ± 0.23 0.88 ± 0.48 0.13
HMW-APN, μg/mL 4.53 ± 2.86 6.4 ± 4.22 0.026 4.1 ± 2.58 5.4 ± 3.17 0.075 6.8 ± 3.6 8.2 ± 5.23 0.85
HMW-APN/BMI 0.18 ± 0.13 0.25 ± 0.19 0.035 0.16 ± 0.11 0.21 ± 0.13 0.081 0.28 ± 0.18 0.33 ± 0.24 0.81
HMW-APN/APN 0.46 ± 0.2 0.57 ± 0.23 0.033 0.42 ± 0.15 0.55 ± 0.24 0.057 0.68 ± 0.32 0.60 ± 0.21 0.81
APN adiponectin, HMW-APN high molecular weight adiponectin, BMI body mass index, mSASSS modified Stoke Ankylosing Spondylitis Spine Score.
aMann-Whitney U test
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levels in patients with AS [35–37]. A meta-analysis from
Mei et al, which included eight studies that had com-
pared leptin levels in patients with AS with those in
healthy controls, came to the conclusion that there are
no significant differences in leptin levels in patients with
AS vs. controls [38]. Differences in serum APN (in-
cluding the HMW isoform) have also not been identi-
fied at group level in patients with AS and healthy
controls [17, 32, 34]. However, in one study serum
APN was higher in male patients with AS versus
healthy controls, and at the same time there was
almost no correlation between leptin or APN and
inflammatory activity, and anti-inflammatory treat-
ment (anti-TNF-α) did not have an effect on serum
leptin and APN [35].
Data on the association between structural damage
in the spine and leptin in AS are very limited. In one
study, higher serum leptin was positively associated
with the presence of syndesmophytes in a cross-
sectional analysis; however, no prospective data were
reported [36]. In the aforementioned study of patients
with early axial SpA, APN was only numerically
higher in non-progressors, but the HMW isoform was
not investigated [17].
What are the possible mechanisms linking leptin
and adiponectin with radiographic spinal progression
in AS? Adipokines are known to be involved in the
regulation of immune processes, displaying both pro-
inflammatory and anti-inflammatory effects, and in
bone metabolism that explains their possible relation-
ship with the pathophysiology of chronic inflamma-
tory conditions such as rheumatoid arthritis or AS
[21, 22, 39]. Our current observation of a protective
effect of leptin and APN (especially its HMW
isoform) against radiographic spinal progression in AS
can probably be best explained by the effects of both
molecules on the process of osteogenesis, since there
is no association between adipokines and inflamma-
tory activity as measured by CRP.
Many studies have previously assessed the part
played by leptin in bone metabolism; however, pub-
lished data show both positive and negative effects of
leptin on bone formation [40]. Two main regulatory
pathways are currently discussed. One targets the
central nervous system, the other one acts through
peripheral regulation [41]. The peripheral effect is
based on a rather direct interaction of leptin with
several bone cell types. For instance, leptin enhances
new bone formation through interaction with bone
marrow stem cells, which can either differentiate into
osteoblasts or into adipocytes. It promotes differenti-
ation and growth of osteoblasts and enhances bone
mineralization [42–44]. Furthermore, leptin adminis-
tered peripherally can inhibit formation of human
osteoclasts [44, 45].
In contrast, a central regulatory effect of leptin on
bone metabolism is rather anti-osteoproliferative. It
has been shown that bone loss could be induced in
leptin-deficient mice through an intracerebrovascular
infusion of leptin [46], indicating a role of leptin as a
hormone which induces pathways of the sympathetic
nervous system (SNS) through the ventromedial
hypothalamus (VMH), which then results in bone
loss. Further studies have confirmed this theory [47,
48]. The available evidence indicates that leptin binds
to its receptors on neurons of the VMH, which then
activate a signal pathway from the VMH to osteo-
blasts via β2 adrenergic receptors of the SNS.
Table 5 Analysis of the association of leptin and HMW-APN with radiographic spinal progression after 2 years
OR unadjusted 95% CI OR adjusteda 95% CI
Outcome: no mSASSS progression after 2 years (logistic regression)
Leptin, ng/mL 1.06 1.003 to 1.12 1.16 1.03 to 1.29
Leptin/BMI 9.20 1.44 to 58.7 28.7 2.24 to 367.7
HMW-APN, μg/mL 1.12 0.98 to 1.27 1.17 0.99 to 1.38
HMW-APN/BMI 9.68 0.48 to 196.2 10.7 0.35 to 320.6
HMW-APN/APN 10.81 1.25 to 93.5 22.2 1.57 to 313.1
Outcome: no syndesmophyte formation/progression after 2 years (logistic regression)
Leptin, ng/mL 1.07 1.002 to 1.14 1.29 1.11 to 1.50
Leptin/BMI 36.5 3.29 to 404.5 131.9 4.78 to 3638
HMW-APN, μg/mL 1.18 1.01 to 1.39 1.18 0.98 to 1.42
HMW-APN/BMI 34.3 0.89 to 1319 23.8 0.41 to 1382
HMW-APN/APN 10.9 1.11 to 106.3 10.8 0.74 to 156.1
aAdjusted for the presence of syndesmophytes at baseline, C-reactive protein at baseline, sex, non-steroidal anti-inflammatory drugs intake score over 2 years, and
smoking status at baseline. Models with leptin, HMW-APN and HMW-APN/APN ratio were additionally adjusted for body mass index (BMI). APN adiponectin, CI
confidence interval, HMW-APN high molecular weight adiponectin, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, OR odds ratio
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Through the signals of the SNS two cascades in osteo-
blasts are activated leading to increased osteoclast forma-
tion and decreased osteoblast differentiation [41].
Hamrick et al. proved in 2004 that the effects of leptin
on the skeleton differ between skeletal regions. Compar-
ing leptin-deficient obese mice (ob/ob) with lean mice
they found that ob/ob mice had significantly reduced
femoral bone mineral density (BMD), bone mineral con-
tent (BMC), cortical thickness and trabecular bone vol-
ume compared to lean mice. On the other hand, they
found ob/ob mice to have higher BMC, BMD and tra-
becular bone volume in the lumbar spine than the lean
mice. Hence, their study suggests that leptin regulates
bone metabolism differently according to the location
within the skeleton [49]. Martin et al. found in 2007 that
there could be a bimodal threshold response to serum
leptin levels, meaning that slight increases in leptin
might initially stimulate bone formation, while higher
leptin levels inhibit bone formation [50].
Thus, leptin might have contradictory effects on bone
metabolism that also depend on the localization of the
bone. We hypothesize that in patients with AS a higher
level of leptin has protective properties against radio-
graphic spinal progression mainly via the central path-
way with inhibition of excessive new bone formation.
As for APN, different effects on bone metabolism have
been discovered as well, yielding similarly conflicting re-
sults. APN was found to be expressed in osteoblasts
along with its receptors and to stimulate their prolifera-
tion and differentiation, for example, through enhance-
ment of the expression of bone morphogenetic protein 2
(BMP-2) [51–53]. Additionally, APN was found to be
able to suppress osteoclastogenesis and promote osteo-
blastogenesis [54]. However, APN is also able to
Table 6 Analysis of association of leptin and HMW-APN with radiographic spinal progression stratified by sex
OR unadjusted 95% CI OR adjusteda 95% CI
Men (n = 82)
Outcome: no mSASSS progression ≥2 points after 2 years (logistic regression)
Leptin, ng/mL 1.20 1.06 to 1.36 1.45 1.18 to 1.78
Leptin/BMI 725.2 15.4 to 34099 4818.9 33.3 to 698123
HMW-APN μg/mL 1.25 1.002 to 1.57 1.35 1.04 to 1.75
HMW-APN/BMI 81.8 0.53 to 12683 186.4 0.63 to 54915
HMW-APN/APN 40.5 2.01 to 813.9 173.6 4.03 to 7479
Outcome: no syndesmophyte formation/progression after 2 years (logistic regression)
Leptin, ng/mL 1.06 0.97 to 1.16 1.34 1.11 to 1.62
Leptin/BMI 54.5 1.99 to 1491 241.8 3.51 to 16651
HMW-APN, μg/mL 1.20 0.97 to 1.48 1.21 0.95 to 1.53
HMW-APN/BMI 55.3 0.37 to 8262 77.9 0.32 to 19249
HMW-APN/APN 31.5 1.60 to 621.5 55.6 1.56 to 1973
Women (n = 38)
Outcome: no mSASSS progression ≥2 points after 2 years (logistic regression)
Leptin, ng/mL 1.01 0.96 to 1.07 1.04 0.95 to 1.14
Leptin/BMI 1.53 0.21 to 11.29 1.67 0.15 to 18.8
HMW-APN, μg/mL 0.99 0.85 to 1.17 1.04 0.85 to 1.27
HMW-APN/BMI 1.22 0.03 to 48.9 3.03 0.05 to 196.9
HMW-APN/APN 0.69 0.02 to 30.4 0.47 0.003 to 68.6
Outcome: no syndesmophyte formation/progression after 2 years (logistic regression)
Leptin, ng/mL 1.05 0.95 to 1.16 1.17 0.90 to 1.51
Leptin/BMI 20.5 0.23 to 1872 18.7 0.06 to 5989
HMW-APN, μg/mL 1.07 0.83 to 1.38 1.13 0.84 to 1.51
HMW-APN/BMI 3.48 0.02 to 738.3 14.8 0.03 to 7869
HMW-APN/APN 0.15 0.001 to 21.4 0.15 0.0004 to 59.5
aAdjusted for the presence of syndesmophytes at baseline, C-reactive protein at baseline, non-steroidal anti-inflammatory drugs intake score over two years, and
smoking status at baseline. Models with leptin, high molecular weight adiponectin (HMW-APN) and HMW-APN/adiponectin (APN) ratio were additionally adjusted
for body mass index (BMI). CI confidence interval, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, OR odds ratio
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indirectly activate osteoclasts by stimulating receptor ac-
tivator of nuclear factor kappa-B (NFкB) ligand
(RANKL) and inhibiting osteoprotegerin (OPG) produc-
tion in osteoblasts, which are known to be essential
stimulators of osteoclastogenesis [55].
An inverse relationship between APN and BMD was
found in vivo in a number of studies [39] indicating that
APN might have predominantly catabolic effects on bone.
In line with this, the meta-analysis of Biver et al., which in-
cluded 59 studies of healthy male and female patients who
were evaluated for BMD or fracture risk and adipokines,
showed that APN seems to be the most important adipo-
kine that is negatively associated with BMD [56].
There are two main circulating isoforms of APN in
the blood stream: one low molecular weight (LMW)
hexamer and the HMW multimer [28, 57]. Previous data
suggest that HMW-APN might be the predominantly
active isoform and that the HMW-APN/APN ratio
might be an important determinant of the metabolic
effects of the hormone [28]. The importance of the
HMW-APN/APN ratio was also confirmed in another
study, in which the ratio was a better predictor of insulin
resistance and metabolic syndrome than total plasma
APN [58]. In line with these data, we found that
HMW-APN (and to a further extent the HMW-APN/
APN ratio) was inversely associated with radiographic
spinal progression in AS, and the association between
radiographic progression and HMW-APN was better
than that between radiographic progression and total
APN.
Our study has limitations. First, this was an analysis
based on a population of a randomized controlled trial. Al-
though we corrected our analysis for differences in the
intervention, we cannot completely exclude bias resulting
from treatment. Further, only relatively few women were
included in this trial, which made the interpretation of the
subgroup analysis results difficult in this population. Also,
no fat mass measurement was performed in the ENRA-
DAS trial beyond BMI calculation. Finally, since no bio-
logic agents were allowed in the ENRADAS trial it is
currently unclear whether leptin and HMW-APN
might also have protective effects against radiographic
spinal progression in patients treated with anti-TNF
or anti-interleukin-17 drugs. Therefore, an independ-
ent validation of our results is highly desirable not
only in patients treated with NSAIDs but also in patients
undergoing biologic treatment. Despite a significant asso-
ciation with radiographic spinal progression, leptin or
HMW-APN alone would not be sufficient for identifica-
tion of patients at high (or low) risk of radiographic spinal
progression. However, these biomarkers seem to be good
candidates for inclusion in multi-parameter predictive
models for estimation of the risk of radiographic spinal
progression in AS.
Conclusion
Serum levels of leptin and HMW-APN are inversely as-
sociated with radiographic spinal progression in patients
with AS. Current data on the role of adipokines in bone
metabolism indicates that leptin and HMW-APN might
not only be markers but also true pathophysiological
factors influencing new bone formation in AS. Female
patients with AS have a higher level of leptin and APN,
which might play a natural protective role against radio-
graphic spinal progression in AS, explaining the gener-
ally lower prevalence of extended new bone formation in
the spine in female patients with AS.
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